Patients With Chronic HBV Infection Show Sustained HBsAg, HBV DNA Loss After 24 Weeks Of Bepirovirsen Therapy, Trial Finds
December 12, 2022
Infectious Disease Advisor (12/9, Nye) reported, “Patients with chronic hepatitis B virus (HBV) infection show sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss after 24 weeks of bepirovirsen therapy, according to” a “phase 2b, randomized, pa...